Dai ichi Life Insurance Company Ltd Has $14.56 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Dai ichi Life Insurance Company Ltd lifted its stake in Zoetis Inc. (NYSE:ZTS) by 16.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 74,499 shares of the company’s stock after acquiring an additional 10,427 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Zoetis were worth $14,556,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in Zoetis during the 3rd quarter worth approximately $31,000. First Personal Financial Services bought a new position in shares of Zoetis during the third quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis in the third quarter valued at approximately $33,000. Quarry LP increased its stake in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the period. Finally, LRI Investments LLC acquired a new position in Zoetis in the 1st quarter valued at $43,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.0 %

Shares of NYSE:ZTS opened at $178.70 on Tuesday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock’s 50-day moving average price is $185.31 and its 200-day moving average price is $180.79. The stock has a market capitalization of $80.62 billion, a P/E ratio of 33.59, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.36 earnings per share. On average, equities analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is 32.52%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ZTS shares. Piper Sandler increased their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus raised their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.